ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!Accesswire • 07/26/24
Allarity Therapeutics, Inc. (ALLR) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky InvestigatesAccesswire • 07/25/24
ALLR Investors Have The Opportunity To Join The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law FirmAccesswire • 07/25/24
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!Accesswire • 07/25/24
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmBusiness Wire • 07/25/24
Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALLRBusiness Wire • 07/24/24
Lost Money on Allarity Therapeutics, Inc.(ALLR)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 07/24/24
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse SplitInvestorPlace • 07/24/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of InvestorsBusiness Wire • 07/24/24
Investigation Into Allarity Therapeutics, Inc. (ALLR) Announced by Holzer & Holzer, LLCGlobeNewsWire • 07/24/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of InvestorsBusiness Wire • 07/24/24
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesGlobeNewsWire • 07/24/24
Reinhausen Manufacturing Inc Celebrates Ribbon Cutting for Plant Expansion in HumboldtBusiness Wire • 07/23/24
The Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of InvestorsBusiness Wire • 07/23/24
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining ComplianceGlobeNewsWire • 06/27/24
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementGlobeNewsWire • 05/20/24
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesGlobeNewsWire • 05/14/24
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to BuyZacks Investment Research • 05/07/24
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockGlobeNewsWire • 05/07/24
Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1GlobeNewsWire • 05/06/24
Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerGlobeNewsWire • 05/02/24
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementGlobeNewsWire • 04/29/24